Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer

Cancer Research

Volumn 66, Issue 8, 2006, Pages 4049-4054

  Jin, Seuk Kim ^a   Jin, Wook Kim ^b   Han, Joungho ^c   Young, Mog Shim ^c   Park, Joobae ^a,c   Kim, Duk Hwan ^a,c  

^a Samsung Medical Center   (South Korea)

^b Seoul Science High School   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; FRAGILE HISTIDINE TRIAD PROTEIN; GLUTATHIONE TRANSFERASE P1; PARAFFIN; PROTEIN P16; RETINOIC ACID RECEPTOR BETA;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL;

ACID ANHYDRIDE HYDROLASES; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; FEMALE; GENES, P16; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33646230046     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3813     Document Type: Article

References (39)

1. Thomas P, Rubinstein L; Lung Cancer Study Group. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Ann Thorac Surg 1990;49:242-7.
2. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage 1 lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9.
3. Kim YT, Lee SH, Sung SW, Kim JH. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection. Ann Thorac Surg 2005;79:1180-8.
4. Zöchbauer-Müller S, Minna JD, Gazdar AF. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 2002;7:451-7.
5. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-speciflc PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
6. Kim HJ, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small cell lung cancer. J Clin Oncol 2004;22: 2363-70.
7. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-55.
8. 1 phase progression: cycling on cue. Cell 1994;79:551-5.
9. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
10. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
11. Kamb A, Guis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
12. Mascaux C, Martin B, Verdebout JM, Meert AP, Ninane V, Sculier JP. Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53. Eur Respir J 2003;21:753-8.
13. Burke L, Khan MA, Freedman AN, et al. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 1998;58:2533-6.
14. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999;59:3333-9.
15. Dumon KR, Ishii H, Vecchione A, et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001;61:4827-36.
16. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci U S A 2002;99:3615-20.
17. Sevignani C, Calin GA, Cesari CR, et al. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res 2003;63:1183-7.
18. Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A 1999;96:8489-92.
19. Ishii H, Dumon KR, Vecchione A, et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001;61:1578-84.
20. Pavelic K, Krizanac S, Cacev T, et al. Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas. Mol Med 2001;7:442-53.
21. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-6.
22. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7.
23. INK4a promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000;18:3221-9.
24. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
25. Soria J-C, Rodriguez M, Liu DD, Lee JJ, Hong WW, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 2002;62:351-5.
26. Zöchbauer-Müller S, Lam S, Toyooka S, et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 2003;107:612-6.
27. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032-7.
28. Geradts J, Fong KM, Zimmerman PV, Minna JD. Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 2000;82:1191-7.
29. Nelson HH, Wiencke JK, Gunn L, Wain JC, Christiani DC, Kelsey KT. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998;58:1804-7.
30. Braakhuis BJM, Brakenhoff RH, Leemans CR. Second field tumors: a new opportunity for cancer prevention? Oncologist 2005;10:493-500.
31. Slaughter DP, Southwick HW, Smejkal W. "Field cancerization" in oral stratified squamous epithelium. Cancer 1953;6:963-8.
32. Ottey M, Han S-Y, Druck T, et al. Fhit deficient normal cancer cells are mitomycin C and UVC resistant. Br J Cancer 2004;91:1669-77.
33. Fong LYY, Fidanza V, Zanesi N, et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci U S A 2000;97:4742-7.
34. Turner B, Ottey M, Otoczek M, et al. The FHIT/ FRA3B locus and repair deficient cancers. Cancer Res 2002;62:4054-60.
35. Hu B, Han S-Y, Wang X et al. Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol 2005;202:518-23.
36. Thomas PA, Jr., Rubinstein L. Malignant disease appearing late after operation for T1N0 non-small cell lung cancer. The Lung Cancer Study Group. J Thorac Cardiovasc Surg 1993;106:1053-8.
37. Okada M, Nishio W, Sakamoto T, Harada H, Uchino K, Tsubota N. Long-term survival and prognostic factors of five-year survivors with complete resection of non-small cell lung carcinoma. J Thorac Cardiovasc Surg 2003;126:558-62.
38. Ramacciato G, Paolini A, Volpino P, et al. Modality of failure following resection of stage I and stage II non-small cell lung cancer. Int Surg 1995;80:156-61.
39. Rena O, Oliaro A, Cavallo A, et al. Stage I non-small cell lung carcinoma: really an early stage? Eur J Cardiovasc Surg 2002;21:514-9.